Teva Pharmaceutical Industries (TEVA) Aandelenoverzicht
Teva Pharmaceutical Industries Limited ontwikkelt, produceert, verkoopt en distribueert generieke en andere geneesmiddelen en biofarmaceutische producten in de Verenigde Staten, Europa, Israël en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
TEVA Community Fair Values
Create NarrativeSee what 93 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Teva Pharmaceutical Industries Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$33.58 |
| 52 Week Hoogtepunt | US$37.35 |
| 52 Week Laag | US$14.99 |
| Bèta | 0.85 |
| 1 maand verandering | -6.31% |
| 3 maanden verandering | 14.61% |
| 1 Jaar Verandering | 93.88% |
| 3 jaar verandering | 350.13% |
| 5 jaar verandering | 217.69% |
| Verandering sinds IPO | 8,165.85% |
Recent nieuws en updates
Narratiefupdate • Jun 08
TEVA: Neuroscience Pipeline And Branded Shift May Support 2026 Multiple Reappraisal
Teva Pharmaceutical Industries' analyst price target has been adjusted from $40.27 to $41.27, as analysts factor in updated assumptions for revenue growth, profit margins and future P/E, supported by a series of recent price target increases from major research firms. Analyst Commentary Recent price target revisions for Teva Pharmaceutical Industries cluster tightly in favor of higher valuations, with several large firms, including JPMorgan, lifting their targets by between US$1 and US$6.Narratiefupdate • May 25
TEVA: Focused R&D In Neuroscience And Immunology Will Support 2026 Multiple Reappraisal
Analyst price targets on Teva Pharmaceutical Industries have edged higher, with the updated fair value estimate moving from about $40.09 to $40.27 as analysts factor in recent target increases and their views on the company’s R&D focus, core therapeutic areas, biosimilars business, and capital deployment plans. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries points to a cluster of higher price targets, with several bullish analysts updating their models after discussions with management about research priorities, therapeutic focus, biosimilars, and capital deployment.Recent updates
Narratiefupdate • Jun 08
TEVA: Neuroscience Pipeline And Branded Shift May Support 2026 Multiple Reappraisal
Teva Pharmaceutical Industries' analyst price target has been adjusted from $40.27 to $41.27, as analysts factor in updated assumptions for revenue growth, profit margins and future P/E, supported by a series of recent price target increases from major research firms. Analyst Commentary Recent price target revisions for Teva Pharmaceutical Industries cluster tightly in favor of higher valuations, with several large firms, including JPMorgan, lifting their targets by between US$1 and US$6.Narratiefupdate • May 25
TEVA: Focused R&D In Neuroscience And Immunology Will Support 2026 Multiple Reappraisal
Analyst price targets on Teva Pharmaceutical Industries have edged higher, with the updated fair value estimate moving from about $40.09 to $40.27 as analysts factor in recent target increases and their views on the company’s R&D focus, core therapeutic areas, biosimilars business, and capital deployment plans. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries points to a cluster of higher price targets, with several bullish analysts updating their models after discussions with management about research priorities, therapeutic focus, biosimilars, and capital deployment.Seeking Alpha • May 25
TEVA's Growth Story Is No Longer Just Generic, It's Getting Branded
Summary Teva Pharmaceutical (TEVA) delivered a strong Q1 2026, reinforcing my buy rating and the company's successful pivot to innovative growth assets. TEVA's innovative neuroscience franchise—AUSTEDO, AJOVY, and Uzedy—drove $838M in Q1 revenue, up 41% year over year, offsetting legacy generics decline. Management maintained full-year guidance, with stable gross margins (52.9%) and a clear path to 30% non-GAAP operating income margin by 2027. Pipeline credibility is rising, biosimilars are gaining traction, and the pending Emalex acquisition adds further innovative growth optionality. Read the full article on Seeking AlphaNarratiefupdate • May 04
TEVA: Neuroscience And Immunology Pipeline Will Drive 2026 Multiple Reappraisal
Analysts lifted the Teva Pharmaceutical Industries price target to $40.09 from $38.18, citing updated assumptions that point to higher revenue growth expectations, a slightly lower projected profit margin, and a higher future P/E multiple. This view is supported by recent research notes highlighting management's R&D focus, build out in core therapeutic areas, biosimilars vision, and capital deployment plans.Narratiefupdate • Apr 16
TEVA: Neuroscience And Immunology R&D And Biosimilars Will Shape 2026 Reappraisal
Analysts have nudged their Teva Pharmaceutical Industries price targets higher, with the model fair value moving from $37.82 to $38.18. This change is supported by updated views on the company's R&D focus in neuroscience and immunology, its biosimilars plans, capital deployment, and the evolving outlook for partnered assets such as duvakitug.
Nieuw narratief • Apr 09
Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine
Catalysts About Teva Pharmaceutical Industries Teva Pharmaceutical Industries develops and sells generic medicines, biosimilars and branded therapies across central nervous system, respiratory and immunology related diseases. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Apr 02
TEVA: Neuroscience And Immunology Pipeline Progress Will Shape 2026 R&D Reappraisal
Narrative Update on Teva Pharmaceutical Industries The analyst price target framework for Teva Pharmaceutical Industries has shifted modestly higher, with recent Street targets moving into the mid to high $30s and low $40s as analysts cite progress in R&D across neuroscience, immunology and biosimilars, improved capital structure and clearer long term EBITDA growth visibility. This comes even as the updated fair value estimate edges from $38.14 to $37.82 on slightly lower modeled revenue growth and profit margins, along with a marginally higher future P/E assumption.Narratiefupdate • Mar 18
TEVA: 2026 Neuroscience And Immunology Pipeline Progress Will Drive Bullish Outlook
Teva Pharmaceutical Industries' analyst price target is modestly higher, with recent $1 to $9 upward revisions tied to analysts' expectations for R&D progress in neuroscience and immunology, a growing biosimilars presence, and stronger cash generation that supports a slightly richer forward P/E multiple. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries focus on how the pipeline, cash generation, and balance sheet shape both upside potential and execution risks.Narratiefupdate • Mar 04
TEVA: Affordable Medicines And 2026 Pipeline Catalysts Will Drive Bullish Outlook
Analysts have nudged their price target for Teva Pharmaceutical Industries up to $38 from $37, reflecting a slightly higher fair value estimate and updated assumptions around long term revenue growth, margins, and the potential for duvakitug to reach $3b in peak sales following recent Phase 2 data with Sanofi. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries highlight a mix of enthusiasm around the pipeline and affordability theme, alongside caution around execution risk and legal overhangs.Narratiefupdate • Feb 18
TEVA: Affordable Medicines And 2026 R&D Progress Will Shape Medium Term Outlook
Narrative Update Overview The analyst price target for Teva Pharmaceutical Industries has been revised modestly higher to $37.95, with analysts pointing to updated fair value estimates, slightly adjusted discount rates, a new revenue growth outlook, and recent Street research highlighting potential pipeline catalysts and the appeal of affordable medicines heading into 2026. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries has centered on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme.Narratiefupdate • Feb 04
TEVA: Affordable Medicines And 2026 Pipeline Milestones Will Shape Medium Term Outlook
Analysts have raised their price targets on Teva Pharmaceutical Industries into a tighter valuation range, with our fair value estimate moving from US$35.32 to US$36.77. They point to improving profit margin assumptions, a lower future P/E, and support from recent research highlighting the affordable medicines theme and potential pipeline catalysts into 2026.Narratiefupdate • Jan 20
TEVA: Affordable Medicines And 2026 Pipeline Catalysts Should Support Re Rating
Narrative Update Analysts have lifted their price target range for Teva Pharmaceutical Industries toward the mid US$30s, reflecting updated assumptions on fair value, profit margins, and future P/E as they point to affordable medicines and potential R&D catalysts around 2026 as key drivers of sentiment. Analyst Commentary Recent street research points to a more constructive tone around Teva Pharmaceutical Industries, with higher price targets tied to its focus on affordable medicines and potential R&D catalysts around 2026.Narratiefupdate • Jan 06
TEVA: Shares Will Hold Steady As Q3 Trends Support Balanced Outlook
Analysts have nudged their price target for Teva Pharmaceutical Industries higher to about US$24, citing recent Q3 pricing and volume trends for key drugs and consistent expectations for earnings across commercial-stage biopharma names. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$24 price target as a reflection of steadier execution on key drugs, with recent Q3 pricing and volume trends supporting their valuation framework.Narratiefupdate • Dec 22
TEVA: Shares Will Trade Sideways As IRA Pricing Clarity Drives Relief Rally
Analysts have raised their fair value estimate for Teva Pharmaceutical Industries to approximately $32.77 from about $28.61, citing recent price target increases to the mid 20 dollar range, expectations for stable Q3 performance, and a potential relief rally tied to upcoming Austedo IRA pricing clarity. Analyst Commentary Recent Street research reflects a generally constructive stance on Teva, with price targets moving higher in anticipation of stable near term execution and clearer visibility on Austedo economics under the Inflation Reduction Act.Narratiefupdate • Dec 08
TEVA: Shares Will Trade Sideways As Drug Pricing Clarity Supports Margins
Analysts have nudged their average price target for Teva Pharmaceutical Industries higher from approximately $27.90 to about $28.60, citing stable near term earnings expectations, improving profit margin assumptions, and a potential relief rally tied to clarity on Austedo pricing under the IRA framework. Analyst Commentary Bullish analysts highlight that recent price target increases reflect growing confidence in Teva's ability to execute on its turnaround strategy and sustain earnings stability, even as broader biopharma peers face mixed revisions.Narratiefupdate • Nov 24
TEVA: Shares Will Rally As IRA Drug Pricing Clarity Approaches
Teva Pharmaceutical Industries' analyst price target has been raised modestly, with analysts citing improved key drug performance and potential relief as regulatory pricing clarity emerges. This reflects a shift from approximately $27.45 to $27.90 per share.Analyseartikel • Nov 13
We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative
Shareholders appeared to be happy with Teva Pharmaceutical Industries Limited's ( NYSE:TEVA ) solid earnings report...Analyseartikel • Nov 12
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Teva Pharmaceutical Industries Limited ( NYSE:TEVA ) shares have been powering on, with...Narratiefupdate • Nov 07
TEVA: Stock Will Gain Momentum As Key Drug Pricing Decision Nears
Analysts have increased their price target for Teva Pharmaceutical Industries by approximately $3, citing improved Q3 trends as well as positive expectations for key drug pricing and regulatory developments. Analyst Commentary Recent updates from Street research highlight both optimistic outlooks and ongoing risks for Teva Pharmaceutical Industries as analysts revise their expectations following Q3 performance and future drug pricing developments.Narratiefupdate • Oct 23
Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries
Teva Pharmaceutical Industries' analyst price target has increased modestly, rising by $0.22 to approximately $24.44 per share. Analysts cite improved pricing and volume trends, along with positive expectations for key drugs and limited Q3 surprises.Narratiefupdate • Oct 09
Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand
Teva Pharmaceutical Industries saw its analyst price target increase modestly from $23.89 to $24.22 per share. Analysts cite anticipated relief rallies and favorable prospects for the company's Austedo pricing strategy.Narratiefupdate • Sep 25
Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand
As Teva Pharmaceutical Industries’ future P/E and revenue growth forecasts remain essentially unchanged, the consensus analyst price target is also largely flat, with a slight increase from $23.56 to $23.89. What's in the News UZEDY, Teva's long-acting injectable risperidone for schizophrenia, secured South Korean regulatory approval and has reached strong commercial milestones, recording $117 million in 2024 net sales and $95 million in the first half of 2025.Analyseartikel • Jul 14
Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nieuw narratief • Apr 23
Generics And Biosimilars Pipeline And Expansion Will Define Progress
The Pivot to Growth strategy targets revenue enhancement through product innovation, operational efficiency, and a sustainable generics business.Seeking Alpha • Feb 28
Teva Pharmaceutical: A Risky Bet With Potential Upside
Summary Teva Pharmaceutical faces challenges with high debt, legal issues, and pricing pressure, but is shifting focus to higher-margin biosimilars and specialty drugs. Despite trading at a low 6.56x forward earnings, Teva's high debt-to-EBITDA ratio and declining earnings are significant concerns. The company's push into biosimilars is promising, but execution and market competition will be critical for success. Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and profitability issues. Read the full article on Seeking AlphaSeeking Alpha • Jan 30
Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
Summary Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be outperformed, and a desirable entry point for long-term investors. Teva Pharmaceutical's pipeline, including Duvakitug and multiple biosimilars, offers significant growth prospects, with several key Phase 3 milestones and potential launches from 2025 to 2027. Teva's aggressive debt reduction enhances financial stability, paving the way for future shareholder-friendly activities like dividends or share repurchases. A 12-month price target of $25/share, 10x FY 2025 non-GAAP EPS estimates seems achievable should Teva outperform lowered EPS and sales estimates. Read the full article on Seeking AlphaSeeking Alpha • Dec 27
Duvakitug And Teva's Growth: A Game Changer In Pharma
Summary On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis. However, a month and a half before this news, the Israeli pharmaceutical company pleased investors by once again beating analysts' expectations by a wide margin. So, Uzedy's sales amounted to $35 million in the third quarter of 2024, increasing more than 16 times year-on-year. Meanwhile, sales of Teva's generics in North America reached $1.09 billion for the three months ended September 30, 2024, up 30.4% from the same period a year earlier. In addition to decreasing its net debt by more than $1 billion in the first three quarters of2024, in this article, you will discover why I continue to cover Teva Pharmaceuticals with a “Buy” rating. Read the full article on Seeking AlphaSeeking Alpha • Dec 04
Teva: Becoming Increasingly Solid, But No Longer Undervalued
Summary Teva's stock has risen 105% in two years, outperforming the S&P 500, but it is no longer a bargain at $17.50 per share. The company's focus on debt reduction has been successful, with net debt falling to $15.70 billion, but high interest expenses remain a concern. Key drugs like AUSTEDO®, AJOVY®, and UZEDY® are driving revenue growth, with AUSTEDO® showing the most promise due to long patent life and rising demand. Despite strong performance and growth in generics and biosimilars, I recommend holding Teva stock, valuing it at $15 per share. Read the full article on Seeking AlphaSeeking Alpha • Oct 23
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Summary Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing drugs on the market across multiple clinical segments, including cancer drugs. Debt to equity is high vs peers; however, debt is on a declining trend. A key risk in pharma space, both financial and reputational, is facing costly legal/regulatory cases. Read the full article on Seeking AlphaSeeking Alpha • Sep 09
Cheap Teva Stock Should Reward Patient Investors
Summary Teva is poised to benefit from rising demand for generic drugs due to a favorable macro and political environment. The company's valuation is attractive despite its high debt load, which it is likely to manage effectively. Teva's generic drug revenue surged 16% in Q2, and the unit's continued growth is expected to significantly boost the firm's overall revenue. Governments and consumers are increasingly opting for cost-effective generic drugs. The latter trend is likely to help boost demand for Teva's generic products. Read the full article on Seeking AlphaSeeking Alpha • Aug 14
Teva's Transformation: From Generics Leader To Branded Drug Innovator
Summary Step by step, Teva's management is making progress in transforming it from a generic drugmaker into one that will play a key role in the fight against immune-related disorders. Its revenue was about $4.16 billion in the second quarter of 2024, up 7.2% year-on-year. So, in addition to the growth in sales of its generic products, there is also increased demand for innovative medications, including Austedo and Uzedy. One of the key milestones in Teva's history will be the publication of results from a clinical trial evaluating the efficacy of duvakitug in the treatment of inflammatory bowel disease in late 2024. Ultimately, I continue to cover Teva Pharmaceutical with a 'Buy' rating. Read the full article on Seeking AlphaRendement voor aandeelhouders
| TEVA | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 2.3% | 5.6% | -3.3% |
| 1Y | 93.9% | 37.6% | 22.3% |
Rendement versus industrie: TEVA overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 37.6 % opleverde.
Rendement versus markt: TEVA overtrof de US markt, die het afgelopen jaar een rendement opleverde van 22.3 %.
Prijsvolatiliteit
| TEVA volatility | |
|---|---|
| TEVA Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: TEVA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van TEVA is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1901 | 32,008 | Richard Francis | www.tevapharm.com |
Teva Pharmaceutical Industries Limited ontwikkelt, produceert, brengt op de markt en distribueert generieke en andere geneesmiddelen, evenals biofarmaceutische producten in de Verenigde Staten, Europa, Israël en wereldwijd. Het bedrijf biedt generieke geneesmiddelen aan in verschillende toedieningsvormen, zoals tabletten, capsules, injectables, inhalatiemiddelen, vloeistoffen, transdermale pleisters, zalven en crèmes; steriele producten, hormonen, krachtige geneesmiddelen en cytotoxische stoffen in parenterale en vaste toedieningsvormen; en generieke producten met medische hulpmiddelen en combinatieproducten. Het bedrijf richt zich ook op het centrale zenuwstelsel (CZS), de luchtwegen, oncologie en andere gebieden.
Teva Pharmaceutical Industries Limited Samenvatting
| TEVA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$40.11b |
| Inkomsten(TTM) | US$1.57b |
| Inkomsten(TTM) | US$17.35b |
25.0x
Koers/Winstverhouding2.3x
P/S-verhoudingIs TEVA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| TEVA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$17.35b |
| Kosten van inkomsten | US$8.32b |
| Brutowinst | US$9.03b |
| Overige uitgaven | US$7.47b |
| Inkomsten | US$1.57b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 1.34 |
| Brutomarge | 52.06% |
| Nettowinstmarge | 9.02% |
| Schuld/Eigen Vermogen Verhouding | 202.2% |
Hoe presteerde TEVA op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/10 21:56 |
| Aandelenkoers aan het einde van de dag | 2026/06/10 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Teva Pharmaceutical Industries Limited wordt gevolgd door 45 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Balaji Prasad | Barclays |
| Glen Santangelo | Barclays |